✦ LIBER ✦

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

✍ Scribed by R. Bissonnette; Y. Poulin; Y. Zhou; J. Tan; H.C. Hong; J. Webster; W. Ip; L. Tang; M. Lyle

Book ID: 108672136
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 336 KB
Volume: 166
Category: Article
ISSN: 0007-0963
DOI: 10.1111/j.1365-2133.2011.10775.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of oral alitretinoin

Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial

✍ T. Ruzicka; C.W. Lynde; G.B.E. Jemec; T. Diepgen; J. Berth-Jones; P.J. Coenraads 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ W. Rigby; H.-P. Tony; K. Oelke; B. Combe; A. Laster; C. A. von Muhlen; E. Fishel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

A phase IIIb, multicentre, randomized, d

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study

✍ D. Thaçi; J.-P. Ortonne; S. Chimenti; P.-D. Ghislain; P. Arenberger; K. Kragball 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ P. P. Tak; P. J. Mease; M. C. Genovese; J. Kremer; B. Haraoui; Y. Tanaka; C. O. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

Tocilizumab inhibits structural joint da

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year

✍ Joel M. Kremer; Ricardo Blanco; Marek Brzosko; Ruben Burgos-Vargas; Anne-Marie H 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB 👁 3 views